ImmuCell Corporation (ICCC) - Net Assets
Based on the latest financial reports, ImmuCell Corporation (ICCC) has net assets worth $29.14 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($44.11 Million) and total liabilities ($14.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ImmuCell Corporation tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $29.14 Million |
| % of Total Assets | 66.05% |
| Annual Growth Rate | 5.93% |
| 5-Year Change | -16.95% |
| 10-Year Change | 37.18% |
| Growth Volatility | 24.99 |
ImmuCell Corporation - Net Assets Trend (1989–2025)
This chart illustrates how ImmuCell Corporation's net assets have evolved over time, based on quarterly financial data. See ImmuCell Corporation (ICCC) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for ImmuCell Corporation (1989–2025)
The table below shows the annual net assets of ImmuCell Corporation from 1989 to 2025. For live valuation and market cap data, see ImmuCell Corporation (ICCC) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $27.06 Million | -1.68% |
| 2024-12-31 | $27.52 Million | +10.10% |
| 2023-12-31 | $24.99 Million | -17.73% |
| 2022-12-31 | $30.38 Million | -6.74% |
| 2021-12-31 | $32.58 Million | +15.25% |
| 2020-12-31 | $28.27 Million | -2.50% |
| 2019-12-31 | $28.99 Million | +33.33% |
| 2018-12-31 | $21.74 Million | -7.84% |
| 2017-12-31 | $23.59 Million | +19.64% |
| 2016-12-31 | $19.72 Million | +85.82% |
| 2015-12-31 | $10.61 Million | +14.64% |
| 2014-12-31 | $9.26 Million | -1.46% |
| 2013-12-31 | $9.40 Million | +2.19% |
| 2012-12-31 | $9.19 Million | +1.93% |
| 2011-12-31 | $9.02 Million | -2.82% |
| 2010-12-31 | $9.28 Million | -3.53% |
| 2009-12-31 | $9.62 Million | -0.23% |
| 2008-12-31 | $9.64 Million | -4.11% |
| 2007-12-31 | $10.06 Million | +7.77% |
| 2006-12-31 | $9.33 Million | +9.05% |
| 2005-12-31 | $8.56 Million | +10.72% |
| 2004-12-31 | $7.73 Million | +4.86% |
| 2003-12-31 | $7.37 Million | +5.98% |
| 2002-12-31 | $6.95 Million | +15.03% |
| 2001-12-31 | $6.05 Million | +9.15% |
| 2000-12-31 | $5.54 Million | +96.74% |
| 1999-12-31 | $2.82 Million | +27.97% |
| 1998-12-31 | $2.20 Million | -4.35% |
| 1997-12-31 | $2.30 Million | +21.05% |
| 1996-12-31 | $1.90 Million | 0.00% |
| 1995-12-31 | $1.90 Million | 0.00% |
| 1994-12-31 | $1.90 Million | -17.39% |
| 1993-12-31 | $2.30 Million | +27.78% |
| 1992-12-31 | $1.80 Million | +20.00% |
| 1991-12-31 | $1.50 Million | -46.43% |
| 1990-12-31 | $2.80 Million | -17.65% |
| 1989-12-31 | $3.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ImmuCell Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1160375300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $910.56K | 3.37% |
| Other Components | $41.35 Million | 152.83% |
| Total Equity | $27.06 Million | 100.00% |
ImmuCell Corporation Competitors by Market Cap
The table below lists competitors of ImmuCell Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Calisa Acquisition Corp Ordinary shares
NASDAQ:ALIS
|
$84.91 Million |
|
Neuraxis, Inc.
NYSE MKT:NRXS
|
$84.91 Million |
|
Bathurst Resources Ltd
AU:BRL
|
$84.93 Million |
|
Tambun Indah Land Bhd
KLSE:5191
|
$84.93 Million |
|
Sumber Energi Andalan Tbk PT
JK:ITMA
|
$84.88 Million |
|
DT Cloud Star Acquisition Corporation Units
NASDAQ:DTSQU
|
$84.88 Million |
|
Freetrailer Group A/S
ST:FREETR
|
$84.85 Million |
|
Quantum Graphite Ltd
AU:QGL
|
$84.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ImmuCell Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 27,518,187 to 27,055,480, a change of -462,707 (-1.7%).
- Net loss of 1,040,027 reduced equity.
- New share issuances of 349,326 increased equity.
- Other comprehensive income decreased equity by 26,411,671.
- Other factors increased equity by 26,639,665.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.04 Million | -3.84% |
| Share Issuances | $349.33K | +1.29% |
| Other Comprehensive Income | $-26.41 Million | -97.62% |
| Other Changes | $26.64 Million | +98.46% |
| Total Change | $- | -1.68% |
Book Value vs Market Value Analysis
This analysis compares ImmuCell Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.13x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5.50x to 3.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1989-12-31 | $1.71 | $9.39 | x |
| 1990-12-31 | $1.31 | $9.39 | x |
| 1991-12-31 | $0.74 | $9.39 | x |
| 1992-12-31 | $0.99 | $9.39 | x |
| 1993-12-31 | $0.87 | $9.39 | x |
| 1994-12-31 | $0.72 | $9.39 | x |
| 1995-12-31 | $0.76 | $9.39 | x |
| 1996-12-31 | $0.70 | $9.39 | x |
| 1997-12-31 | $0.77 | $9.39 | x |
| 1998-12-31 | $0.91 | $9.39 | x |
| 1999-12-31 | $1.12 | $9.39 | x |
| 2000-12-31 | $1.96 | $9.39 | x |
| 2001-12-31 | $2.16 | $9.39 | x |
| 2002-12-31 | $2.51 | $9.39 | x |
| 2003-12-31 | $2.61 | $9.39 | x |
| 2004-12-31 | $2.61 | $9.39 | x |
| 2005-12-31 | $2.85 | $9.39 | x |
| 2006-12-31 | $3.06 | $9.39 | x |
| 2007-12-31 | $3.31 | $9.39 | x |
| 2008-12-31 | $3.33 | $9.39 | x |
| 2009-12-31 | $3.25 | $9.39 | x |
| 2010-12-31 | $3.12 | $9.39 | x |
| 2011-12-31 | $3.02 | $9.39 | x |
| 2012-12-31 | $2.96 | $9.39 | x |
| 2013-12-31 | $3.05 | $9.39 | x |
| 2014-12-31 | $3.06 | $9.39 | x |
| 2015-12-31 | $3.35 | $9.39 | x |
| 2016-12-31 | $4.55 | $9.39 | x |
| 2017-12-31 | $4.77 | $9.39 | x |
| 2018-12-31 | $3.96 | $9.39 | x |
| 2019-12-31 | $4.25 | $9.39 | x |
| 2020-12-31 | $3.92 | $9.39 | x |
| 2021-12-31 | $4.29 | $9.39 | x |
| 2022-12-31 | $3.92 | $9.39 | x |
| 2023-12-31 | $3.23 | $9.39 | x |
| 2024-12-31 | $3.37 | $9.39 | x |
| 2025-12-31 | $3.00 | $9.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ImmuCell Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3.76%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.57x
- Recent ROE (-3.84%) is below the historical average (-3.22%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1989 | -29.41% | -35.71% | 0.70x | 1.18x | $-1.34 Million |
| 1990 | -21.43% | -20.00% | 0.88x | 1.21x | $-880.00K |
| 1991 | -93.33% | -63.64% | 1.00x | 1.47x | $-1.55 Million |
| 1992 | -11.11% | -6.45% | 1.35x | 1.28x | $-380.00K |
| 1994 | -5.26% | -2.27% | 1.42x | 1.63x | $-290.00K |
| 1996 | -5.26% | -2.27% | 1.42x | 1.63x | $-290.00K |
| 1997 | 13.04% | 6.52% | 1.44x | 1.39x | $70.00K |
| 1998 | -4.55% | -2.22% | 1.45x | 1.41x | $-320.00K |
| 1999 | 19.57% | 11.22% | 1.27x | 1.37x | $269.30K |
| 2000 | 40.12% | 39.43% | 0.87x | 1.16x | $1.67 Million |
| 2001 | 6.95% | 6.29% | 0.94x | 1.18x | $-184.60K |
| 2002 | 12.74% | 14.33% | 0.82x | 1.08x | $190.78K |
| 2003 | 5.58% | 12.25% | 0.41x | 1.11x | $-325.83K |
| 2004 | 1.86% | 3.88% | 0.39x | 1.23x | $-629.37K |
| 2005 | 8.27% | 14.20% | 0.50x | 1.16x | $-147.97K |
| 2006 | 6.93% | 13.48% | 0.42x | 1.22x | $-286.06K |
| 2007 | 6.58% | 10.91% | 0.58x | 1.04x | $-343.56K |
| 2008 | -4.86% | -10.11% | 0.46x | 1.05x | $-1.43 Million |
| 2009 | -2.25% | -4.80% | 0.45x | 1.04x | $-1.18 Million |
| 2010 | -4.14% | -8.77% | 0.41x | 1.16x | $-1.31 Million |
| 2011 | -4.54% | -8.01% | 0.47x | 1.22x | $-1.31 Million |
| 2012 | 0.97% | 1.66% | 0.49x | 1.20x | $-829.96K |
| 2013 | 1.25% | 1.95% | 0.55x | 1.17x | $-822.19K |
| 2014 | -1.81% | -2.20% | 0.69x | 1.19x | $-1.09 Million |
| 2015 | 11.43% | 11.86% | 0.70x | 1.38x | $151.86K |
| 2016 | 2.58% | 5.33% | 0.39x | 1.25x | $-1.46 Million |
| 2017 | -0.71% | -1.61% | 0.30x | 1.45x | $-2.53 Million |
| 2018 | -10.68% | -21.14% | 0.34x | 1.51x | $-4.50 Million |
| 2019 | -4.47% | -9.44% | 0.35x | 1.33x | $-4.20 Million |
| 2020 | -3.62% | -6.66% | 0.38x | 1.43x | $-3.85 Million |
| 2021 | -0.24% | -0.41% | 0.43x | 1.36x | $-3.34 Million |
| 2022 | -8.21% | -13.43% | 0.41x | 1.48x | $-5.53 Million |
| 2023 | -23.10% | -33.05% | 0.40x | 1.75x | $-8.27 Million |
| 2024 | -7.84% | -8.14% | 0.59x | 1.64x | $-4.91 Million |
| 2025 | -3.84% | -3.76% | 0.65x | 1.57x | $-3.75 Million |
Industry Comparison
This section compares ImmuCell Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ImmuCell Corporation (ICCC) | $29.14 Million | -29.41% | 0.51x | $84.90 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavir… Read more